Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutrition 21 names new president and CEO
Mr Zeher most recently served as president and CEO of Nutritional Laboratories International. Prior to joining Nutritional Labs, Mr Zeher was president and COO of Pharmaceutical Formulations. Mr
Mr Zeher most recently served as president and CEO of Nutritional Laboratories International. Prior to joining Nutritional Labs, Mr Zeher was president and COO of Pharmaceutical Formulations. Mr
The proceeds from this financing are expected to fund additional commercialization, product development and clinical research efforts for the company, which serves the $4 billion spinal market. This
The SpineAlign vertebral body replacement system (VBR) is SpineWorks Medical’s first approved product that was designed for a transpedicular, minimally-invasive approach to vertebral body reconstruction and anterior spinal
Orchem has registered Spectrum 24 with the US Environmental Protection Agency as a sub-registrant of Pure Bioscience and is currently undergoing registration in all 50 states. In accordance
The study is designed to determine the maximum tolerated dose and to establish the recommended dose and dosing schedule for Phase II trials, and will evaluate the safety
Light Sciences Oncology (LSO) plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing Phase III clinical trials in patients
The agreement, which initially runs over five years, has a total estimated value of approximately RMB61.5 million. To date, China Sky One has been selling five of its
Dr Stamler brings to XenoPort over 15 years of clinical development experience, most recently serving as the chief scientific officer and head of drug development for Prestwick Pharmaceuticals.
First, it is alleged that Teva tested Copaxone on amyotrophic lateral sclerosis patients despite the failure of the drug in previous trials on mice. However, the company vouched
A former employee of Roche lodged a complaint against the company citing an article published in the Financial Times. The article alleged that Roche had sold large quantities